ADX71149

Janssen Pharmaceuticals, Inc. (JPI), formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson company is developing mGluR2 PAM under a 2004 agreement with Addex. The lead indications for this project include anxiety and schizophrenia. Several series of mGluR2 PAMs were discovered and the lead product, ADX71149, is undergoing Phase IIa testing for schizophrenia.

In 2007 Addex completed its responsibilities in the discovery phase of the agreement. Preclinical and clinical development are Johnson & Johnson’s responsibility, although Addex will participate via a joint steering committee. Addex is eligible for development and regulatory milestones of up to a total of EUR109 million plus low double-digit royalties. To date, Addex has received a €3 million upfront payment, €4.3 million in research funding and a €1 milllion milestone payment when ADX71149 entered the clinic in June 2009.

mGluR2 & anxiety
mGluRs & schizophrenia